Primary hyperparathyroidism in patients who have received radiation therapy and in patients who have not received radiation therapy

• Published in: Journal of the American College of Surgeons Vol. 180; no. 1; p. 81
• Main Authors: Tezelman, S, Rodriguez, J M, Shen, W, Siperstein, A E, Duh, Q Y, Clark, O H
• Format: Journal Article
• Language: English
• Published: United States 01.01.1995
• Subjects: Adolescent; Adult; Calcium - blood; Child; Female; Humans; Hyperparathyroidism - blood; Hyperparathyroidism - etiology; Male; Middle Aged; Neoplasms, Radiation-Induced - blood; Neoplasms, Radiation-Induced - etiology; Parathyroid Hormone - blood; Radiation Dosage; Radiotherapy - adverse effects; Retrospective Studies; Thyroid Neoplasms - blood; Thyroid Neoplasms - etiology
• ISSN: 1072-7515

Primary hyperparathyroidism (HPT) occurs more frequently in persons who have been exposed to low-dose therapeutic radiation. Little information is available concerning whether or not the clinical, metabolic, and pathologic manifestations, as well as outcome, differ in these patients when compared with patients with sporadic HPT. Records from 438 unselected patients with primary HPT, who were treated from 1982 to 1993 were retrospectively analyzed. All patients prospectively received a standard questionnaire preoperatively and postoperatively concerning clinical manifestations and a history of radiation exposure. Forty-nine patients had a history of radiation exposure (rHPT), whereas 389 did not have sporadic HPT (sHPT). There was no difference in gender (36 women and 13 men versus 289 women and 100 men) or age (mean of 52 +/- 12 versus 57 +/- 16 years) in patients with rHPT or sHPT. Fatigue, neuropsychiatric disorders, memory loss, nocturia, and polyurea were more common in patients with sHPT (p < 0.05), whereas pain in joints was more common in patients with rHPT (63 versus 52 percent; p < 0.001). Serum calcium levels were similar (11.1 +/- 0.8 versus 11.2 +/- 0.8 mg per dL), but serum parathyroid hormone levels were higher in rHPT (448 +/- 14 percent of upper limit of normal versus 371 +/- 12 percent upper limit of normal). The parathyroid pathology was similar in the two groups (single adenoma 74 versus 72 percent, hyperplasia 14 versus 16 percent, and double adenoma 12 versus 12 percent in rHPT versus sHPT, respectively). Thyroid pathology was more common in the rHPT group (multinodular goiter 27 versus 7 percent and papillary thyroid carcinoma 14 versus 0.3 percent). Seven (1.8 percent) of patients not receiving radiation therapy treated by us had persistent HPT, but no patients receiving or not receiving radiation therapy had recurrent HPT during the follow-up period (six years). Patients who have HPT after radiation treatment have more thyroid neoplasms but are otherwise quite similar to other patients with primary hyperparathyroidism.